Metabolic dysfunction-associated fatty liver disease (MAFLD) was associated with higher levels of the cholesterol-high-density lipoprotein glucose (CHG) index, with increasing levels also linked to greater hepatic steatosis severity, according to a cross-sectional study of more than 22,000 adults.
Findings suggest that the composite metabolic marker may help identify individuals with MAFLD.
Assessing the CHG Index and MAFLD
Researchers analysed health examination data from 22,858 adults who attended the Health Management Centre. Of these participants 34.3% were diagnosed with MAFLD using abdominal ultrasound findings and metabolic dysfunction criteria.
The CHG index combines total cholesterol, high-density lipoprotein cholesterol and fasting blood glucose measurements. Researchers investigated its association with MAFLD and compared its ability to distinguish individuals with the condition against the triglyceride-glucose (TyG) index.
After adjustment for age, sex, body mass index and other clinical factors, each standard deviation increase in CHG was associated with higher odds of prevalent MAFLD.
CHG Levels Increase with Steatosis Severity
Researchers also examined CHG levels across ultrasound-defined categories of hepatic steatosis. Median CHG levels increased from 5.09 among participants without steatosis to 5.42 in those with mild steatosis and 5.52 in those with moderate-to-severe steatosis.
Following adjustment for potential confounders, each standard deviation increase in CHG was associated with higher odds of mild steatosis and moderate-to-severe steatosis, compared with no steatosis.
Further Validation Required
Researchers noted that the cross-sectional design prevented conclusions about causality or whether higher CHG levels precede the development of MAFLD. Additionally, hepatic steatosis was assessed using ultrasound rather than more precise methods such as liver biopsy or MRI-derived proton density fat fraction.
Researchers concluded that CHG was positively associated with prevalent MAFLD and greater ultrasound-defined hepatic steatosis severity. However, independent validation is needed to establish whether the index offers additional diagnostic value and has a role in clinical assessment.
Reference :
Lin Y et al. Association of the cholesterol-high-density lipoprotein glucose index with metabolic dysfunction-associated fatty liver disease and hepatic steatosis severity: a cross-sectional study based on health examination data. BMC Gastroenterology.2026; DOI: 10.1186/s12876-026-05579-7.